Research paper reviews the efficacy of the first licensed malaria vaccines, RTS,S and R21, highlighting their potential to significantly reduce childhood mortality and discussing future vaccine development strategies.
CMN-005 by CoImmune for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
CMN-005 is under clinical development by CoImmune and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).